European Journal of Clinical Pharmacology

, Volume 71, Issue 11, pp 1325–1332 | Cite as

Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis

  • Ting Yang
  • Min Lu
  • Lingyue Ma
  • Ying Zhou
  • Yimin Cui
Pharmacodynamics

Abstract

Purpose

The aim of this study is to assess the efficacy and tolerability of canagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, added on to metformin in patients with type 2 diabetes mellitus (T2DM).

Methods

Literatures were searched from major electronic databases, as well as the Chinese State Food and Drug Administration and clinicaltrials.gov for unpublished studies. Only randomized controlled trials (RCTs) comparing canagliflozin with placebo in combination with metformin were included. Two reviewers independently selected studies, evaluated the risk of bias, and extracted data. The included RCTs were analyzed by the software RevMan 5.3 provided by the Cochrane Collaboration.

Results

Six RCTs were chosen for the meta-analysis. Compared to placebo, canagliflozin produced absolute reduction in glycated hemoglobin A1c (HbA1c) (−0.66 % [−0.72 %, −0.61 %]). The proportion of patients who achieved target HbA1c was significantly greater in the canagliflozin-treated group (1.86 [1.69, 2.03]). Canagliflozin led to greater fasting plasma glucose (FPG) reduction of 1.49 mmol/L (100 mg/day) and 1.80 mmol/L (300 mg/day). Significant body weight loss of 2.09 % (100 mg/day) and 2.66 % (300 mg/day) with canagliflozin was observed. Canagliflozin was found to improve β cell function in terms of homeostasis model assessment (HOMA2-%B) (15.59 % [12.84 %, 18.35 %]). Higher incidences of genital mycotic infection/female and pollakiuria (increased urine frequency) were noted with canagliflozin compared with placebo-controlled groups.

Conclusions

Canagliflozin is a potential option as an add-on to metformin based on its improvement in HbA1c, FPG, body weight, and β cell function, but further studies are demanded to strengthen this evidence. Common adverse events (AEs) like genital mycotic infection/female and pollakiuria were identified.

Keywords

Canagliflozin Metformin Type 2 diabetes Meta-analysis 

Supplementary material

228_2015_1923_MOESM1_ESM.docx (18 kb)
ESM 1(DOCX 17 kb)
228_2015_1923_MOESM2_ESM.docx (32 kb)
ESM 2(DOCX 32 kb)

References

  1. 1.
    Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103(2):137–149CrossRefPubMedGoogle Scholar
  2. 2.
    Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating G (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378 (9785):31–40.Google Scholar
  3. 3.
    American Diabetes A (2015) (7) Approaches to glycemic treatment. Diabetes Care 38 Suppl:S41-48.Google Scholar
  4. 4.
    Brown JB, Conner C, Nichols GA (2010) Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 33(3):501–506PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378(9786):182–197CrossRefPubMedGoogle Scholar
  6. 6.
    Hardman TC, Dubrey SW (2011) Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2(3):133–145PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54(12):3427–3434CrossRefPubMedGoogle Scholar
  8. 8.
    Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27(2):136–142PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Neumiller JJ, White Jr. JR, Campbell RK (2010) Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70(4):377–385CrossRefPubMedGoogle Scholar
  10. 10.
    Nair S, Wilding JP (2010) Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 95(1):34–42CrossRefPubMedGoogle Scholar
  11. 11.
    Riser Taylor S, Harris KB (2013) The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 33(9):984–999CrossRefPubMedGoogle Scholar
  12. 12.
    Canagliflozin (Invokana) for type 2 diabetes (2013). Med Lett Drugs Ther 55 (1416):37–39Google Scholar
  13. 13.
    Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4):372–382PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36(9):2508–2515PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Polidori D, Zhao Y, Alba M, Ferrannini E (2012) Treatment with canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, for 26 weeks improves indices of betacell function (BCF). Diabetes 61:A265Google Scholar
  16. 16.
    Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D, Group CTC (2015) Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 38(3):403–411CrossRefGoogle Scholar
  17. 17.
    Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G (2015) Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 38(3):355–364Google Scholar
  18. 18.
    Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H (2014) Efficacy and safety of canagliflozin monotherapy in japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, phase III study. Expert Opin Pharmaco 15(11):1501–1515CrossRefGoogle Scholar
  19. 19.
    Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H (2013) Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 15(12):1136–1145PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Inagaki N, Kondo K, Yoshinari T, Kuki H (2015) Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in japanese patients with type 2 diabetes: a 52-week open-label study. J Diabetes Investig 6(2):210–218PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S (2012) Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14(6):539–545Google Scholar
  22. 22.
    Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941–950Google Scholar
  23. 23.
    Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K (2013) Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 41(2):72–84CrossRefGoogle Scholar
  24. 24.
    Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 16(5):467–477Google Scholar
  25. 25.
    Ji L, Han P, Liu Y, Yang G, Dieu Van NK, Vijapurkar U, Qiu R, Meininger G (2015) Canagliflozin in asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab 17(1):23–31CrossRefPubMedGoogle Scholar
  26. 26.
    Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56(12):2582–2592PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Qiu R, Capuano G, Meininger G (2014) Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J Clin and Transl Endocr 1(2):54–60Google Scholar
  28. 28.
    Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes care 35(6):1232–1238PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67(12):1267–1282PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Zhang Q, Dou J, Lu J (2014) Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract 105(3):313–321CrossRefPubMedGoogle Scholar
  31. 31.
    Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org
  32. 32.
    Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH (2009) The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9:88PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13(7):669–672CrossRefPubMedGoogle Scholar
  34. 34.
    Kahn SE (2001) Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86(9):4047–4058PubMedGoogle Scholar
  35. 35.
    Kahleova H, Mari A, Nofrate V, Matoulek M, Kazdova L, Hill M, Pelikanova T (2012) Improvement in beta-cell function after diet-induced weight loss is associated with decrease in pancreatic polypeptide in subjects with type 2 diabetes. J Diabetes Complicat 26(5):442–449CrossRefPubMedGoogle Scholar
  36. 36.
    Polidori D, Mari A, Ferrannini E (2014) Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 57(5):891–901PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Diels J, Angermund R, Schroeder M, Worbes-Cerezo M, Thompson G (2014) The efficacy and effectiveness in HbA1c-lowering is dependent on baseline body mass index (BMI) for sitagliptin but not canagliflozin in the treatment of type 2 diabetes mellitus (T2DM). Value Health 17(7):A334CrossRefGoogle Scholar
  38. 38.
    Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K (2014) Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 30(6):1109–1119CrossRefPubMedGoogle Scholar
  39. 39.
    Nyirjesy P, Zhao Y, Ways K, Usiskin K (2012) Evaluation of vulvovaginal symptoms and candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 28(7):1173–1178CrossRefPubMedGoogle Scholar
  40. 40.
    Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13(7):669–672CrossRefPubMedGoogle Scholar
  41. 41.
    Yang XP, Lai D, Zhong XY, Shen HP, Huang YL (2014) Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 70(10):1149–1158CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Ting Yang
    • 1
  • Min Lu
    • 1
  • Lingyue Ma
    • 1
  • Ying Zhou
    • 1
  • Yimin Cui
    • 1
  1. 1.Department of PharmacyPeking University First HospitalBeijingPeople’s Republic of China

Personalised recommendations